Measuring and mapping the global burden of antimicrobial resistance

The increasing number and global distribution of pathogens resistant to antimicrobial drugs is potentially one of the greatest threats to global health, leading to health crises arising from infections that were once easy to treat. Infections resistant to antimicrobial treatment frequently result in...

Full description

Saved in:
Bibliographic Details
Published inBMC medicine Vol. 16; no. 1; p. 78
Main Authors Hay, Simon I, Rao, Puja C, Dolecek, Christiane, Day, Nicholas P J, Stergachis, Andy, Lopez, Alan D, Murray, Christopher J L
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 04.06.2018
BioMed Central
BMC
Subjects
Ambulatory care
Animals
Anti-infective agents
Antibiotics
Antiinfectives and antibacterials
Antimicrobial agents
Antimicrobial drugs
Antimicrobial resistance
Bacteria
Complications and side effects
Data collection
Disease
Dosage and administration
Drug resistance
Drug-resistant infections
Epidemiology
Estimates
Fatalities
Geographical distribution
Global health
Health aspects
Health risks
Infections
Injuries
Laboratories
Low income groups
Microbial
Microbial drug resistance
Morbidity
Mortality
Risk factors
Sepsis
Surveillance
Viral infections
United States
Africa
Antimicrobial drugs
Global health
Global burden of disease
Drug-resistant infections
Anti-infective agents
Microbial
Antimicrobial resistance
Public health
Online AccessGet full text

Cover

More Information
Summary:The increasing number and global distribution of pathogens resistant to antimicrobial drugs is potentially one of the greatest threats to global health, leading to health crises arising from infections that were once easy to treat. Infections resistant to antimicrobial treatment frequently result in longer hospital stays, higher medical costs, and increased mortality. Despite the long-standing recognition of antimicrobial resistance (AMR) across many settings, there is surprisingly poor information about its geographical distribution over time and trends in its population prevalence and incidence. This makes reliable assessments of the health burden attributable to AMR difficult, weakening the evidence base to drive forward research and policy agendas to combat AMR. The inclusion of mortality and morbidity data related to drug-resistant infections into the annual Global Burden of Disease Study should help fill this policy void.
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
ISSN:1741-7015
1741-7015
DOI:10.1186/s12916-018-1073-z